RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
AssigneeSirna Therapeutics, Inc.
InventorsJames McSwiggen, Leonid Beigelman
Life of this patent
Estimating the term…
Loading patent…
AssigneeSirna Therapeutics, Inc.
InventorsJames McSwiggen, Leonid Beigelman
Estimating the term…
This invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase (e.g., checkpoint kinase-1 or CHK-1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of checkpoint kinase gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of checkpoint kinase genes.
A chemically modified double stranded nucleic acid molecule comprising a sense strand and an antisense strand, wherein:
Dependencies are inferred from the claim text.